THJ-2201

THJ-2201
Systematic (IUPAC) name
[1-(5-Fluoropentyl)-1H-indazol-3-yl](1-naphthyl)methanone
Clinical data
Legal status
Identifiers
CAS Number 972102-31-2 YesY
PubChem CID 91864533
ChemSpider 30646749
Chemical data
Formula C23H21FN2O
Molar mass 360.42 g/mol

THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3]

It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.[4]

Side effects

THJ-2201 has been linked to at least one hospitalization and death due to its use.[5]

Legal status

Because of the hazards associated with recreational use of this compound,[6] it is classified as a Schedule I controlled substance in the United States.[7]

It is also an Anlage II controlled drug in Germany.[8]

See also

References

  1. Xingxing Diao, Ariane Wohlfarth, Shaokun Pang, Karl B. Scheidweiler, Marilyn A. Huestis (October 2015). "High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes". Clinical Chemistry. doi:10.1373/clinchem.2015.243535. PMID 26430074.
  2. Shevyrin, Vadim; Melkozerov, Vladimir; Nevero, Alexander; Eltsov, Oleg; Morzherin, Yuri; Shafran, Yuri (2014). "3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: Chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures". Forensic Science International 242: 72–80. doi:10.1016/j.forsciint.2014.06.022. PMID 25036783.
  3. Nahoko Uchiyama, Yoshihiko Shimokawa, Maiko Kawamura, Ruri Kikura-Hanajiri, Takashi Hakamatsuka (August 2014). "Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products". Forensic Toxicology 32 (2): 266–281. doi:10.1007/s11419-014-0238-5.
  4. "THJ-2201". Cayman Chemical. Retrieved 21 July 2015.
  5. Jordan Trecki, Roy R. Gerona, Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
  6. Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration (December 2014). "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone (THJ-2201): Background Information and Evaluation of ‘Three Factor Analysis’ (Factors 4, 5, and 6) for Temporary Scheduling" (PDF).
  7. Drug Enforcement Administration, Department of Justice (2015). "Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order". Federal register 80 (20): 5042–7. PMID 25730924.
  8. "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)". Retrieved 9 July 2015.


This article is issued from Wikipedia - version of the Friday, February 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.